iSpecimen Inc. splits its revenue into 2 lines in its filings. The largest line in Q2 of fiscal 2026, the quarter ended Jun 30, 2026 was Product at $125,435, 83% of the total.
USD in millions. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Jun 30, 2026
|
Q2 FY2026
Jun 30, 2026
|
Q1 FY2026
Mar 31, 2026
|
Q4 FY2025
Dec 31, 2025
|
Q3 FY2025
Sep 30, 2025
|
Q2 FY2025
Jun 30, 2025
|
Q1 FY2025
Mar 31, 2025
|
Q4 FY2024
Dec 31, 2024
|
Q3 FY2024
Sep 30, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
0
|
0
|
0
|
0
|
0
|
1
|
1
|
—
|
3
|
| Product |
0
-93.8%
share 74.2%
|
0
-81.3%
share 82.6%
|
0
-86.2%
share 86.2%
|
-0
-100.7%
share -18.3%
|
0
-96.4%
share 89.9%
|
1
share 94.2%
|
1
share 92.4%
|
1
|
3
share 98.7%
|
| Shipping And Handling |
0
-57.4%
share 25.8%
|
0
-36.0%
share 17.4%
|
0
-73.2%
share 13.8%
|
0
-51.0%
share 118.3%
|
0
-69.2%
share 10.1%
|
0
share 5.8%
|
0
share 7.6%
|
0
|
0
share 1.3%
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Services-Commercial Physical & Biological Research (SIC 8731)
- Listed as
- ISPC (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Woburn, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1558569
Other Services-Commercial Physical & Biological Research companies
- Iqvia Holdings Inc. IQV
- Incyte Corp INCY
- Medpace Holdings, Inc. MEDP
- Charles River Laboratories International, Inc. CRL
- Icon PLC ICLR
- Absci Corp ABSI
- OmniAb, Inc. OABI
- NRC Health NRC
All 17 Services-Commercial Physical & Biological Research companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.